Topical capsaicin for the treatment of cannabinoid hyperemesis syndrome, a systematic review and meta-analysis

Cannabinoid hyperemesis syndrome (CHS) is a condition that is being recognized and treated more frequently in emergency departments (EDs) across the United States. Currently, ED providers rely on antiemetics, antipsychotics and benzodiazepines to alleviate the symptoms. Topical capsaicin, a transient receptor potential vanilloid 1 (TRPV1) agonist, has been proposed in recent years as a low-cost and effective alternative to the traditional antiemetic regimen when treating CHS. The aim of this systematic review and meta-analysis is to demonstrate the reliability and the gaps of what is known about the treating modality.
Source: The American Journal of Emergency Medicine - Category: Emergency Medicine Authors: Source Type: research